在非ST升高急性冠状动脉综合征的老年患者中,常规的侵入性与保守的策略
Carlos Diaz-Arocutipa1, Rafael Salguero2,3, Roberto Martín-Asenjo2,3
1Unidad de Revisiones Sistemáticas y Meta-análisis (URSIGET), Vicerrectorado de Investigación, Universidad San Ignacio de Loyola, Lima, Peru.
Expert review of cardiovascular therapy
|July 3, 2025
概括
对于患有非ST段升高急性冠状动脉综合征 (NSTE-ACS) 的老年患者,常规的侵入性策略可以有效降低心血管事件. 这种方法可以减少主要的不良心血管事件和心肌梗塞,而不会增加出血风险,支持个性化护理.
科学领域:
- 心脏病学 心脏病学
- 老年医学 老年医学
- 干预心脏病学 干预心脏病学
背景情况:
- 对于患有非ST段升高急性冠状动脉综合征 (NSTE-ACS) 的老年患者的最佳管理尚未确定.
- 这一系统性审查解决了围绕常规侵入性与保守策略的不确定性.
研究的目的:
- 在被诊断患有NSTE-ACS的老年患者中,系统地审查和评估常规侵入性与保守性管理策略的疗效和安全性.
- 提供证据来支持这个脆弱患者群体的个性化治疗决策.
主要方法:
- 我们对PubMed,Embase和Scopus进行了系统的搜索,搜索到2024年9月发布的随机对照试验 (RCT).
- 七个RCT涉及2,997名老年患者 (平均年龄为81-86岁),被纳入了分析.
- 使用随机效应模型,主要心血管不良事件 (MACE) 作为主要结果和死亡率,心肌梗塞,再血管,中风和出血作为次要结果. 证据确定性的评估是使用GRADE.
主要成果:
- 在老年NSTE-ACS患者中,常规的侵入性策略显著降低了MACE的风险 (HR 0.77,95% CI 0.65-0.92).
- 在心肌梗塞 (HR 0.70) 和再血管 (HR 0.45) 中观察到显著的减少.
- 两种策略之间在全因死亡率,心血管死亡率,中风或出血事件方面没有发现显著差异. 证据的确定性通常是中等的.
结论:
- 对于患有NSTE-ACS的老年患者来说,常规的侵入性策略是有益的,导致心血管事件减少.
- 这种策略似乎不会显著增加出血的风险,支持其在临床实践中的考虑.
- 这些发现支持基于患者特异性因素和风险概况的个性化治疗决策的必要性.
相关概念视频
Acute Coronary Syndrome IV: Interprofessional Care
32
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
32
Acute Coronary Syndrome I: Introduction
80
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
80
Coronary Artery Disease V: Interprofessional Care
38
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
38
Angina V: Nursing Management
54
Angina, a symptom of myocardial ischemia, requires a structured nursing management approach to ensure effective care and prevent complications like myocardial infarction. Comprehensive nursing care involves assessing, diagnosing, planning, implementing interventions, and evaluating outcomes, all tailored to the individual patient's needs.Patient AssessmentNursing assessment begins with a detailed subjective evaluation of symptoms, which typically include chest pain or pressure radiating to the...
54
Angina IV: Management
28
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
28
Atherosclerosis III: Management
41
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
41


